M.D., PhD, FAAN, FEAN, FCAHS

Neurologist. Director of Multiple Sclerosis Centre of Catalonia (Cemcat)

•    Chair of Neurology, Vall d’Hebron University Hospital (HUVH)
•    Chief of the Neuroimmunology Research Group at the Vall d’Hebron Research Institute (VHIR)
•    Vice-president of the Fundació Esclerosi Múltiple (FEM)
•    President of the Cemcat Private Foundation
•    Scientific Committee & Board Member of the European Charcot Foundation (ECF)
•    Vice-chair of the International Advisory Committee on Clinical Trials in MS of the National Multiple Sclerosis Societies (NMSS)
•    Professor of Neurology and Neuroimmunology, Universitat Autònoma de Barcelona (UAB)
•    Professor of Neurology, Universitat de Vic – Universitat Central de Catalunya (UVic-UCC)
•    Member of the International Panel on Multiple Sclerosis Diagnostic Criteria
•    Neuroscience Topic Advisory Group ICD11 of World Health Organization
•    Co-editor/Editor for Clinical Cases, Multiple Sclerosis Journal
•    Multiple Sclerosis Area Director of Revista de Neurología
•    Member of the Editorial Board of Therapeutic  Advances in Neurological Disorders (TAND)
•    Member of the Editorial Board of Multiple Sclerosis Journal
•    Director of the Cemcat Chair of Neuroimmunology

Previous positions:

•    Chair of the International Medical & Scientific Board of the Multiple Sclerosis International Federation (MSIF), 2015-2019)
•    Chair of Neurology-Neuroimmunology, Vall d’Hebron University Hospital (HUVH), 2012-2017
•    President of the European of the Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2014-2016
•    Vicepresident of the Sociedad Española de Neurología (SEN), 2014-2016
•    Member of the Steering Committee of Magnetic Resonance Imaging in MS (MAGNIMS), 1997-2014
•    Member of Scientific Commitee of European School of Neuroimmunology (ESNI), 1999-2013


 

Education

MD and PhD in Neuroimmunology, Universitat Autònoma de Barcelona
Postdoctoral fellowship at the Lupus Research Institute
Clinical training National Hospital for Neurology and Neurosurgery, Queen Square in London (UK)
MBA Esade Business School


Career

Current Appointments 
2017 – present  Chair of Neurology, Vall d’Hebron University Hospital, Barcelona, Spain
2007 – present  Director, CEMCAT, Multiple Sclerosis Center of Catalonia, Vall d’Hebron University Hospital, Barcelona, Spain
2006 – present  Professor of Neurology, UAB, Universitat Autònoma de Barcelona, Barcelona, Spain
2022 – present  Chair of Neurology, UVic-UCC, Universitat de Vic – Universitat Central de Catalunya, Vic, Spain
2021 – present  Professor of Neurology, UVic-UCC, Universitat de Vic – Universitat Central de Catalunya, Vic, Spain
1995 - present  Coordinator, Neuroimmunology, VHIR, Vall d’Hebron University Hospital Research Institute, Barcelona, Spain

Previous Appointments
2017 – 2020    Director of the BarLo MS Centre, Neurology, Department of Medicine, St. Michael’s Hospital, Toronto, Ontario, Canada
2017 – 2020    Director, Division of Neurology, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2017 – 2020    Professor, Neurology, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
2012 - 2017    Chair of Neurology / Neuroimmunology, Vall d’Hebron University Hospital, Barcelona, Spain
2010 - 2012    Clinical Director of Neuroscience, Vall d’Hebron University Hospital, Barcelona, Spain
2005 - 2010    Clinical Head, Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain
1990 - 2007    Head, Clinical Neuroimmunology Unit, Vall d’Hebron University Hospital, Barcelona, Spain


Awards:

2022 John Dystel Prize for Multiple Sclerosis Research (American Academy of Neurology-AAN & National Multiple Sclerosis Society-NMSS)
2021, 2020, 2019 & 2018 Highly Cited Researchers (Web of Science/Clarivate Analytics)
Tribute on the Fundación Merck Salud's 30th anniversary, 2021 (Fundación Merck Salud)
Tribute to individuals whose passion, talent and expertise make the greatest contributions to LACTRIMS in their professional career, 2021 (Latinamerican Committee for Treatment and Research in Multiple Sclerosis-LACTRIMS)
Best in Class 2018 (Gaceta Médica & Chair on Innovation and Health Management of the Rey Juan Carlos University)
Award to the 25 Medical Ambassadors of Spanish Health System 2018 (Diario Médico)
ECTRIMS Honorary Member of the Council, 2017 (European Committee for Treatment and Research in Multiple Sclerosis-ECTRIMS)
Award for Professional Excellence in Biomedical Research 2012 (Official College of Physicians of Barcelona-COMB)
2009 Multiple Sclerosis Award (Spanish Asociation of Neurology-SEN)

 


Projects / Lines of Research / Interests

Prof. Montalban has been in the inception phases and on steering committees of many clinical trials as an expert and key opinion leader in Multiple Sclerosis. He has authored over 750 original and revision publications in International peer-reviewed journals as well as several book chapters.

As a chief of the Neuroimmunology Research Group at the Vall d’Hebron Research Institute (VHIR), he is also working on MR imaging and biological prognostic factors of disease evolution and treatment response, immunological mechanisms of the disease and other aspects of clinical management of MS. Of note in Medicine education is the UAB postgraduate online Master's Degree in Neuroimmunology offered to physicians with some experience in the field.

His research interests include clinical aspects of MS: he has directed the development of the first Spanish (second worldwide) Multiple Sclerosis Clinical Practice Guidelines. He also has led the European Guidelines for Treatment of MS, of which Prof. R. Gold is co-chair.


Bio

Tintore M, Cobo-Calvo A, Carbonell P, Arrambide G, Otero-Romero S, Río J, Tur C, Comabella M, Nos C, Arévalo MJ, Midaglia L, Galán I, Vidal-Jordana A, Castilló J, Rodríguez-Acevedo B, Zabalza de Torres A, Salerno A, Auger C, Sastre-Garriga J, Rovira À, Montalban X. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology. 2021 Oct 26;97(17):e1641-e1652. doi: 10.1212/WNL.0000000000012726. Epub 2021 Sep 14. PMID: 34521693

Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20. PMID: 32690791.

Montalban X, Shaw J, Dangond F, Martin E, Grenningloh R, Weber MS, Vermersch P. Effet de l’Evobrutinib, inhibiteur de la tyrosine kinase de Bruton, sur les taux de cellules immunitaires et d’immunoglobulines sur 48 semaines dans le cadre d’une étude de phase 2 sur la sclérose en plaques récurrente. Rev Neurol (Paris). 2020 Sep;176S:S81. French. doi: 10.1016/j.neurol.2020.01.242. PMID: 32906528.

Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019 May;15(5):287-300. doi: 10.1038/s41582-019-0170-8. Review. PubMed PMID: 30940920.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10. PubMed PMID: 31075187.

Tur C, Kalincik T, Oh J, Sormani MP, Tintoré M, Butzkueven H, Montalban X. Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. Neurology. 2019 Oct 29;93(18):793-809. doi: 10.1212/WNL.0000000000008319. Epub 2019 Oct 7. Review. PubMed PMID: 31591277.

Arrambide G, Tintoré M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana Á, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira À, Comabella M, Montalban X. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018 Apr 1;141(4):1075-1084. doi: 10.1093/brain/awy006. PubMed PMID: 29462277.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F. Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477. doi: 10.1212/NXI.0000000000000477. eCollection 2018 Sep. PubMed PMID: 30027104; PubMed Central PMCID: PMC6047834.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20. Erratum in: Mult Scler. 2020 Apr;26(4):517. PMID: 29353550.

Montalban X, Belachew S, Wolinsky JS. Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. PubMed PMID: 28445663.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. PubMed PMID: 28002688.

Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintoré M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik Barkhof, Xavier Montalban; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis- establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015 Oct;11(10):597-606. doi: 10.1038/nrneurol.2015.157. Epub 2015 Sep 15. Review. PubMed PMID: 26369511.

Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, Montalban X; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015 Aug;11(8):471-82. doi: 10.1038/nrneurol.2015.106. Epub 2015 Jul 7. Review. Erratum in: Nat Rev Neurol. 2015 Aug;11(8):483. PubMed PMID: 26149978.

Tintoré M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Arévalo MJ, Negrotto L, Galán I, Vidal-Jordana Á, Castilló J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. doi: 10.1093/brain/awv105. Epub 2015 Apr 21. PubMed PMID: 25902415.

Montalban X, Comi G, Antel J, O'Connor P, de Vera A, Cremer M, Sfikas N, von Rosenstiel P, Kappos L. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. J Neurol. 2015 Dec;262(12):2627-34. doi: 10.1007/s00415-015-7834-0. Epub 2015 Sep 4. PubMed PMID: 26338810.

Comabella M, Montalban X. Body fluid biomarkers in multiple sclerosis. Lancet Neurol. 2014 Jan;13(1):113-26. doi: 10.1016/S1474-4422(13)70233-3. Review. PubMed PMID: 24331797.

Montalban X, Sastre-Garriga J. Diagnosis and trials of clinically isolated syndrome. Lancet Neurol. 2014 Oct;13(10):962-3. doi: 10.1016/S1474-4422(14)70202-9. Epub 2014 Sep 2. PubMed PMID: 25192850.

Montalban X, Tintoré M. Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measures. Nat Rev Neurol. 2014 Feb;10(2):72-3. doi: 10.1038/nrneurol.2013.274. Epub 2014 Jan 7. Review. PubMed PMID: 24394287.

Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, Atkinson G, Dua P, Yousry T, Macmanus D, Montalban X. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012 Feb;11(2):131-9. doi: 10.1016/S1474-4422(11)70299-X. Epub 2012 Jan 5. PubMed PMID: 22226929.

Gold R, Montalban X. Multiple sclerosis: more pieces of the immunological puzzle. Lancet Neurol. 2012 Jan;11(1):9-10. doi: 10.1016/S1474-4422(11)70268-X. PubMed PMID: 22172612.